Imatinib is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia. Inhibition of c-kit causes melanocyte dysfunction, thereby leading to dermatological side effects. It causes various skin side effects and hypopigmented rash being common. We report a rare case of a hyperpigmented rash of Imatinib.
No takes yet. Share an insight, caveat, or question.
Sood et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: